Please login to the form below

Not currently logged in
Email:
Password:

Shire makes board changes

UK-based pharmaceutical company Shire has revealed its board succession plans

UK-based pharmaceutical company Shire has revealed its board succession plans.

Dr James H Cavanaugh will retire as non-executive chairman and Matthew Emmens will succeed him, while Angus Russell will take over from Emmens as CEO.

David Kappler will be appointed as deputy chairman in addition to his existing role as senior independent director. These appointments have the unanimous support of the directors.

The changes will become effective at Shire's AGM to be held in June 2008.

Cavanaugh has been chairman of Shire since 1999 and will have been a member of the board for 11 years when he retires.

Emmens, who is currently Shire's CEO, has 34 years of industry experience and since joining the company in 2003 has successfully led the company through a period of significant strategic development, including a number of important M&A transactions. He also has valuable non-executive board experience in his continuing roles on the boards of Incyte and Vertex Pharmaceuticals.

Shire's new CEO Angus Russell, who has been CFO since 1999, has eight years experience as the company's CFO and executive board director and has 27 years experience in the pharmaceutical industry including working for ICI, Zeneca and AstraZeneca in finance, strategy and marketing.

Russell has been a lead member of the Shire Management Committee, which devised and implemented Shire's long term focused business strategy. The company is now working to identify a replacement CFO in order to ensure an orderly succession.

Shire is trading in line with the guidance given on 1 November 2007 when it stated that revenue growth for the year was expected to be at least 30 per cent.

13th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics